European Pharmaceutical Review

MARCH 14, 2024

Overall, the goal of expanded facility is to strengthen [SK biosciences] manufacturing capabilities for global supply [of the pneumococcal conjugate vaccine candidate GBP410]” SK bioscience has announced its manufacturing plant L HOUSE, in Andong, Gyeongsangbuk-do, South Korea, is set to have a facility expansion.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

OCTOBER 10, 2022

The RNA Centre of Excellence is the only UK site equipped to develop and manufacture millions of doses of a messenger and self-amplifying RNA vaccines. RNA technology enables vaccines to be developed rapidly, offering potential solutions for diseases such as cancer and cardiovascular disease through the creation of novel therapies.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

AUGUST 15, 2022

According to Reuters , Kenya, Tanzania, Senegal and Cameroon have either run out of or are close to running out of vaccines to protect children against the deadly rotavirus infection following undisclosed “manufacturing challenges” at GSK. million more children missed the third dose of polio vaccine and 3.5 million more than in 2019.

Vaccines 98

Vaccines Communication 98

STAT

SEPTEMBER 12, 2024

The company also said that it plans to break even by 2028, when it expects it will reach annual sales of $6 billion. The announcement was made ahead of a meeting being held by Moderna on Thursday to update investors on its research and development efforts. Continue to STAT+ to read the full story…

Vaccines 126

Vaccines 126

Pharmaceutical Technology

JANUARY 30, 2023

According to GlobalData’s Drugs database, there were 22 prophylactic vaccines in development for COVID-19 with sales forecasts available in H2 2022. These are forecast to generate $264 billion in sales between 2021 and 2028. Likewise, Moderna’s Spikevax, the second leading COVID-19 vaccine with 19.5

Vaccines 52

Vaccines 52

Pharmaceutical Technology

JANUARY 25, 2023

It was an exceptional year for Moderna’s vaccine Spikevax, with forecast sales of $19.5bn in 2022. Spikevax is an mRNA vaccine that is approved in 20 geographies including the US, EU, and, the UK. The vaccine first gained Emergency Use Approval in December 2020 in response to the Covid-19 pandemic.

Vaccines 59

Vaccines 59

European Pharmaceutical Review

NOVEMBER 14, 2023

In response to supply chain challenges, including shortages of critical glass vials for products like COVID-19 vaccines and parenteral drugs, the Packaging and Distribution Expert Committee (PD EC) has made a significant revision of United States Pharmacopeia (USP) General Chapter <660>—Glass.

Packaging 105

Packaging Vaccines Documentation FDA 105

Hospital Pharmacy Europe

JULY 26, 2024

The shingles vaccine that has been used in the NHS since last year is associated with a reduced risk of dementia, researchers have reported. A study of more than 200,000 adults before and after the US switched from Zostavax to the Shingrix vaccine found at least a 17% reduction in dementia diagnoses.

Vaccines 52

Vaccines Immunization Hospitals 52

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

Vaccines 64

Vaccines FDA Immunization 64

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. GlobalData separates immuno-oncology treatments into six broad classes, which include bispecific antibodies, cancer vaccines, and cell therapies.

Immunization 105

Immunization Vaccines Compounding Insurance 105

European Pharmaceutical Review

JANUARY 5, 2023

Moderna’s two Omicron-targeting bivalent COVID-19 vaccines have been approved in more than 70 countries. finalised a strategic partnership to create a state-of-the-art mRNA vaccine research, development, and manufacturing facility in the UK. Moderna’s mRNA therapeutics strategy. At the end 2022, Moderna, Inc.

Vaccines 59

Vaccines 59

pharmaphorum

AUGUST 8, 2022

billion in 2028 – a leap forward from the $195 million it made last year and $127 million in the first half of 2022. The deal is another example of Pfizer splashing out on business development thanks to windfall cash generated by its COVID-19 vaccine Comirnaty and oral antiviral therapy Paxlovid.

Vaccines 111

Vaccines FDA 111

European Pharmaceutical Review

AUGUST 21, 2023

Part of this growth was driven by Arexvy, which in May 2023, became the world’s first approved RSV vaccine for older adults. billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. Merck & Co Merck & Co reached third in ranking, due to 8.4

Vaccines 98

Vaccines FDA 98

European Pharmaceutical Review

OCTOBER 12, 2023

With the goal of supplying cell therapies, vaccines and other essential medicines such as antibody drugs to patients, the facilities aim to address major supply challenges and navigate the intricacies of producing fragile biological products. Subject to planning permission, the site is expected to be opened by 2028. The new £26.4

Vaccines 104

Vaccines Dosage Pharmaceutical Companies Pharmaceutical Companies 104

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Novo Nordisk reported an 18.2%

Vaccines 52

Vaccines FDA 52

PharmaShots

MAY 2, 2023

The US FDA was granted the expanded conditional approval authority in the Animal Drug User Fee Act of 2018 with the program planned to sunset in 2028 The efficacy of molidustat oral suspension had been established based on the results of a study conducted in 2 phases in 23 cats aged 4-17yrs.

FDA 45

FDA Vaccines 45

STAT

SEPTEMBER 12, 2024

In a press release issued ahead of an investor meeting today, the company also said it plans to break even by 2028, when it expects it will reach annual sales of $6 billion.

Packaging 55

Packaging Vaccines 55

Hospital Pharmacy Europe

NOVEMBER 23, 2023

According to the Government, the new VPAG deal – which will run until 31 December 2028 – will help keep the price of vital branded medicines affordable for the NHS. Victoria Atkins, health and social care secretary, said: ‘Millions of NHS patients will benefit from this momentous, UK-wide agreement.

Vaccines 52

Vaccines Hospitals 52

The FDA Law Blog

DECEMBER 3, 2023

CMS will send the final manufacturer invoice for discount liabilities accrued by then on April 30, 2028. covered insulin product or vaccine). Sunsetting of Coverage Gap Discount Program: The 70% coverage gap discount under the CGDP will continue until December 31, 2024. Final Guidance at 2. state pharmaceutical assistance programs).

Labelling 105

Labelling Compounding Payment Processing Vaccines 105

PharmaShots

JUNE 1, 2023

PDC*line is much more potent than conventional dendritic cell-based vaccines in priming and boosting antitumor antigen-specific cytotoxic T-cells, including the T-cells specific for neoantigens, and is synergistic with checkpoint inhibitors. The technology can potentially be applied to any type of cancer.

Immunization 40

Immunization Vaccines Health and Personal Care Stores Labelling 40

Pharmaceutical Technology

APRIL 27, 2023

The successful development and deployment of the mRNA-based COVID-19 vaccines has catalysed the biopharma industry and paved the way to expand this drug modality to new therapeutic areas. billion by 2028. Excluding vaccines, there are five mRNA therapeutic products in clinical trial development as of November 2022.

Vaccines 52

Vaccines Documentation Communication 52

European Pharmaceutical Review

MARCH 12, 2025

MSD has announced it has opened a new $1 billion vaccine manufacturing facility at its site in Durham, North Carolina, US. MSD shared that a further $8 billion of US capital investment is anticipated by 2028.

Research Laboratories 52

Research Laboratories Vaccines 52

European Pharmaceutical Review

MARCH 25, 2025

MSDs recent $1 billion manufacturing investment In another recent investment, earlier this month, MSD opened a new vaccine manufacturing facility in the US. The new vaccine manufacturing facility utilises innovative capabilities such as data analytics, generative AI, as well as 3D printing.

Research Laboratories 52

Research Laboratories Vaccines 52

pharmaphorum

NOVEMBER 4, 2021

Medicare would negotiate up to 10 drugs per year starting in 2023, with the prices taking effect two years later, rising to 20 medicines per year in 2028. “This discourages drug companies from abusing laws to prolong their monopolies, while encouraging investments in research and development of new cures.”

Vaccines 52

Vaccines 52